Phase II study of diamino-dichlorophenyl-methylpyrimidine (DDMP) with folinic acid (CF) protection and rescue.
D000230:Adenocarcinoma / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002648:Child; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005493:Folic Acid Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use*; D007958:Leukocyte Count; D008545:Melanoma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D010976:Platelet Count; D011739:Pyrimethamine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012509:Sarcoma / Q000188:drug therapy
D005493:Folic Acid Antagonists; C006308:metoprine; D002955:Leucovorin; D011739:Pyrimethamine